Cyclobenzaprine Pharmacokinetics, Including the Effects of Age, Gender, and Hepatic Insufficiency

@article{Winchell2002CyclobenzaprinePI,
  title={Cyclobenzaprine Pharmacokinetics, Including the Effects of Age, Gender, and Hepatic Insufficiency},
  author={Gregory A. Winchell and J D King and Cynthia M Chavez-Eng and Marvin L. Constanzer and Scott H. Korn},
  journal={The Journal of Clinical Pharmacology},
  year={2002},
  volume={42}
}
The pharmacokinetics and bioavailability of cyclobenzaprine, a widely used muscle relaxant, were investigated in four clinical studies, and the effects of age, gender, and hepatic insufficiency were characterized. Cyclobenzaprine plasma clearance was 689 ml/min, and the bioavailability of a 5 mg oral dose was 0.55. Following oral doses of 2.5 to 10 mg tid in healthy young subjects, cyclobenzaprine pharmacokinetics were linear, and plasma concentrations generally increased proportional to dose… 
Pharmacokinetics and Bioequivalence Evaluation of Cyclobenzaprine Tablets
TLDR
Bioequivalence was evaluated by means of 90% confidence intervals for the ratio of AUC and C max values for test and reference products, which were within the 80%–125% interval proposed by FDA.
Pharmacokinetic profile of once-daily cyclobenzaprine extended-release
TLDR
This review focuses on the pharmacokinetic profile of a new formulation, cyclobenzaprine extended-release (CER), which delivers a sustained plasma cyclobensaprine concentration over 24 h, allowing once-daily dosing.
Bioavailability of a controlled-release cyclobenzaprine tablet and influence of a high fat meal on bioavailability.
TLDR
The controlled release tablet showed a relative bioavailability comparable with equal dose of the immediate release product and produced a significantly lower Cmax, as expected in a controlled release formulation.
Single-Dose Pharmacokinetics of Once-Daily Cyclobenzaprine Extended Release 30 mg versus Cyclobenzaprine Immediate Release 10 mg Three Times Daily in Healthy Young Adults
TLDR
The pharmacokinetic profile of once-daily CER reflected the mode of administration, providing a controlled release of cyclobenzaprine with sustained plasma concentrations, in contrast to the fluctuating profile of CIR.
Comparative Bioavailability and Pharmacodynamic Aspects of Cyclobenzaprine and Caffeine in Healthy Subjects and the Effect on Drowsiness Intensity
A specific, fast and sensitive LC–MS/MS assay was d e- veloped for the determination of cyclobenzaprine in hu- man plasma using imipramine as the internal standar d (IS). The limit of quantification
Transfer of Cyclobenzaprine into Human Milk and Subsequent Infant Exposure
TLDR
This study shows low levels of concentrations of cyclobenzaprine in human milk with calculated relative infant dose of 0.5%.
The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs
TLDR
A critical clinical perspective on age, sex, and CYP genetic polymorphisms and their role in the metabolism and exposure to anticholinergic drugs is provided to better approach personalized medicine for optimal outcomes and avoidance of medication‐related cognitive impairment.
Inhibition of In Vitro Metabolism of Opioids by Skeletal Muscle Relaxants
TLDR
This first comprehensive study of the inhibitory effect of this class of drugs suggests that some of them may produce significant drug–drug interactions with opioids that are frequent comedications with skeletal muscle relaxants.
...
...

References

SHOWING 1-10 OF 17 REFERENCES
Evidence for route dependent biotransformation of cyclobenzaprine hydrochloride.
TLDR
Urinary excretion and plasma level data for cyclobenzaprine together provide evidence for route dependent biotransformation and area under the plasma concentration-time curve for unchanged cyclobenzaprine was less for the oral treatment than for the parenteral treatments.
Plasma Levels and Bioavailability of Cyclobenzaprine in Human Subjects
TLDR
Comparison of areas under plasma level curves after oral and intravenous doses of cyclobenzaprine suggests that the drug may be partly metabolized in the lumen or during its first passage through the gut wall and/or liver.
Physiological disposition and metabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man.
The absorption, distribution, excretion, and metabolism of 3-(5 H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine (cyclobenzaprine) were investigated in the rat, dog, rhesus monkey, and
Gender‐related differences in pharmacokinetics and their clinical significance
  • E. Tanaka
  • Biology, Medicine
    Journal of clinical pharmacy and therapeutics
  • 1999
TLDR
Gender differences in pharmacokinetics involving the cytochrome P450 (CYP) isozymes of young and mature adults, excluding the effects of the menstrual cycle, use of oral contraceptives and pregnancy are summarized.
Clinical Pharmacokinetics of Antidepressants in the Elderly
TLDR
Much work is still needed to evaluate the relationships among drug concentrations at steady-state, efficacy and adverse effects in the elderly, particularly in the case of tricyclic antidepressants.
Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications.
TLDR
Much work is still needed to evaluate the relationships among drug concentrations at steady-state, efficacy and adverse effects in the elderly, particularly in the case of the tricyclic antidepressants.
Clinical Pharmacokinetic Considerations in the Elderly
TLDR
There is increasing understanding of the diversity of cytochrome P450s and the variability of the age-related decline in CYP activity and the appreciation that selectivity in induction and inhibition in the elderly are due to the existence of multiple CYP forms.
Clinical pharmacokinetic considerations in the elderly. An update.
TLDR
There is increasing understanding of the diversity of cytochrome P450s and the variability of the age-related decline in CYP activity and the appreciation that selectivity in induction and inhibition in the elderly are due to the existence of multiple CYP forms.
Effects of Liver Disease on Pharmacokinetics
TLDR
This review updates recent developments in CYP, with particular emphasis on cytochrome P450, a rapidly expanding area in clinical pharmacology, and examines drugs with altered pharmacodynamics.
GLC determination of cyclobenzaprine in plasma and urine.
TLDR
A GLC determination of cyclobenzaprine in human plasma and urine is described and the N-desmethyl analog of the drug was detected as a metabolite in urine.
...
...